Alpha Teknova just posted the first quarter in its three-decade history that cleared the twelve-million revenue mark, and management used that print to lift full-year guidance and cut the cash-outflow target. The Hollister reagent maker is no longer arguing from a recovery story alone. The live debate is whether catalog and custom Lab Essentials, plus a still-lumpy Clinical Solutions book, can carry the plant to adjusted earnings before interest, taxes, depreciation, and amortization breakeven before the MidCap cash covenant and a live shelf registration force another trip to the equity window.
The second-quarter beat was broad rather than a single-order spike. Lab Essentials and Clinical Solutions each grew 18%. The largest direct customer stayed under 7% of sales. Free cash outflow shrank to $0.6 million. That cash improvement is the operating proof the market wanted after years of post-IPO burn. The offset sits in the one end market that did not grow: cell and gene therapy accounts, where an order slipped into the third quarter and early-stage research demand remains muted. Gross margin reached 40%. The year-ago quarter had notably favorable plant efficiencies, so the sequential jump from the first quarter is the cleaner read.
What the current price already assumes is that this run-rate holds through a seasonally lighter fourth quarter and that commercial hires start converting early next year. What it does not yet have to assume is a biotech-funding tailwind, which management has left out of the back-half guide. The next few prints decide whether Teknova is a self-funding custom-reagent platform or a still-lossy tools name trading as if the capacity build is already earning its keep.